HCA — HCA Healthcare, Inc.

Sentiment is split between a genuinely damaged forward earnings story and a still-constructive street view. On 2026-07-24 HCA reported Q2 2026 revenue of $20.23B (+8.7% YoY) but cut FY2026 guidance to $6.3-6.7B net income and $28.70-30.50 adjusted EPS, citing a ~$400M Q2 pretax hit and a widened $1.0-1.2B full-year ACA-related uninsured/EBITDA headwind. Analysts recalibrated targets downward (JPMorgan $490 to $425, Goldman Sachs $558 to $485) but kept ratings intact — the breakdown is 29 Buy / 15 Hold / 2 Sell with a $455.19 consensus target, only ~6-7% above the 2026-09-13 price. The tape reflects that ambivalence: -19.89% over six months (the guidance reset), but +10.27% over three months and +5.42% in the single week into 2026-09-13, i.e. the market has stopped panicking without becoming optimistic. Core utilization remains solid (same-facility admissions +2.5%, equivalent admissions +2.7% in Q2 2026), which is why this reads Neutral rather than Bearish.

Revenue growth is steady and intact, not accelerating or decelerating: $16.21B (Q3'23) to $17.30B (Q4'23) to $17.34B (Q1'24) to $17.49B (Q2'24) to $17.49B (Q3'24) to $18.29B (Q4'24) to $18.32B (Q1'25) to $18.61B (Q2'25) to $19.16B (Q3'25) to $19.51B (Q4'25) to $19.11B (Q1'26) to $20.23B (Q2'26) — a consistent mid-single-to-high-single-digit YoY cadence, with Q2'26 at +8.7%. The inflection is in margins, not revenue. Operating margin ran 13.78% in Q3'24, 15.56% in Q4'24, 15.58% in Q1'25, 15.95% in Q2'25, 15.47% in Q3'25 and 16.29% in Q4'25 — a real expansion phase — then compressed to 14.98% in Q1'26 (-60bps YoY) and 15.16% in Q2'26 (-79bps YoY). That is the ACA payer-mix shift showing up, and it is a genuine new trend, not a one-quarter blip, because management explicitly widened the full-year headwind to $1.0-1.2B. Earnings per share still grew (Q2'26 diluted EPS $7.62 vs $6.83 in Q2'25, +11.6%) even though net income rose only 2.8% ($1,699M vs $1,653M) — the gap is almost entirely share-count reduction from buybacks, a durable but non-operating source of EPS growth. The one genuine yellow flag: operating cash flow fell to $2,335M in Q2'26 from $4,210M in Q2'25 (-44.5%), though Q2'25 looks elevated versus Q1'25 ($1,651M) and Q3'25 ($4,416M); on a trailing-four-quarter basis OCF is $11.12B versus $11.94B a year earlier (-6.8%), which is a mild deterioration, not a collapse. Trailing FCF is $5.997B (Q3'25 $3,128M + Q4'25 $870M + Q1'26 $895M + Q2'26 $1,104M).

Fair, with a slight cash-flow tilt toward cheap but no real earnings cushion. As of 2026-09-13 the stock traded at 14.25x trailing EPS versus a 5-year average trailing P/E of 13.63x — a small premium to its own history, not the discount the headline number implies — and at roughly 14.4-14.5x forward earnings ($29.60 FY2026 guidance midpoint; $29.47 next-FY consensus). P/S of 1.185 is modestly below the 5-year average of 1.25. PEG of 0.582 looks cheap, but treat it skeptically: it is being flattered by buyback-driven EPS growth rather than organic operating leverage. On cash, EV/EBITDA of 9.02x is right in the middle of the 8-10x hospital-operator band, and trailing FCF of ~$6.0B on a $92.4B market cap is a ~6.0% free-cash-flow yield — genuinely attractive in absolute terms. P/B (-14.47x) and debt/equity (-7.42x) are mathematically meaningless here because stockholders' equity is negative (-$6.58B at 2026-06-30), the product of years of buybacks rather than distress. Net verdict: you are paying a history-average multiple for a business whose earnings are currently being shaved by policy, with a solid cash-flow yield as the offset.

At $426.94 on 2026-09-13, the market is capitalizing roughly the midpoint of the cut FY2026 guidance at ~14.4x — that is neither a recession multiple nor a growth multiple, it is a 'show me' multiple. The setup is binary around one question: is the $1.0-1.2B ACA headwind the full extent of the damage, or the first installment? If Q3 2026 (late October) confirms the uninsured impact has stabilized, EPS estimates stop falling, the buyback keeps compounding a shrinking share count, and a 15x multiple on $30+ of EPS puts $450 back in play — which is where the 200-day moving average and the analyst consensus cluster both sit. If guidance is cut a second time, the market will question the 2027-2028 Medicaid supplemental payment outlook as well and the reference point becomes the $353.99 52-week low. Note that price has already partially priced in the recovery: the stock is +10.27% over three months while estimates were falling, meaning the multiple did the work, not the earnings. That is the risk in owning it here — you are paying up for a stabilization that has not yet been reported.

As of 2026-09-13, RSI(14) was 59.59 — firm momentum, nowhere near overbought. Price was 2.85% above the 20-day SMA (~$415) and 5.42% above the 50-day SMA (~$405), but 5.28% BELOW the 200-day SMA (~$451). That combination — above the short/intermediate averages, below the long one — is a classic repair pattern inside a still-unresolved downtrend, not a confirmed uptrend. The 52-week range is $353.99-$556.52, so the price sits ~21% off the low and ~23% off the high. Timing implication: the +5.42% one-week move into 2026-09-13 is momentum chasing a beaten-down name, and the ~$450 200-day line is the natural resistance/decision point — coincidentally the same zone as the consensus price target. A decisive close above ~$450 would flip the trend structure bullish; failure there keeps this range-bound between roughly $400 and $450 until the October print. Buying today means buying the middle of that range.

• ACA exchange subsidy expiration: the enhanced federal subsidies lapsed, driving an uninsured/self-pay mix shift that management sized at a ~$400M Q2 2026 pretax hit and a $1.0-1.2B full-year EBITDA headwind — this is the single dominant swing factor on HCA's 2026-2027 margins.
• Medicaid and state supplemental payment reform: state-directed payment and supplemental funding programs face structural change heading into 2027-2028; this is a multi-year reimbursement risk that the trailing financials cannot yet show.
• Interest burden and leverage: $38.87B of long-term debt against $60.53B of total assets and only $1.01B of cash and equivalents, with total liabilities ($63.67B) exceeding total assets ($60.53B). Much of the debt is fixed-rate, but refinancing costs and a current ratio of 0.781 leave a thin liquidity cushion.
• Labor cost inflation: nursing and allied-health wage pressure remains the persistent margin swing factor for all acute-care operators, and it is why the 2024-2025 margin expansion (13.78% to 16.29% operating margin across Q3'24-Q4'25) is not guaranteed to resume once ACA pressure eases.
• Defensive sector positioning versus policy risk: hospital operators screen as relatively defensive with solid underlying utilization (Q2 2026 same-facility admissions +2.5%), but the sector is being re-rated on policy uncertainty rather than demand, which caps multiple expansion regardless of volume trends.

• Q3 2026 earnings, expected late October 2026 — the decisive test of whether the ACA-related uninsured impact has stabilized at $1.0-1.2B or requires a further guidance cut; also the first read on whether the Q2 2026 operating cash flow step-down ($2.34B vs $4.21B in Q2 2025) was a collections timing issue or a real deterioration.
• Fall 2026 investor and health care conference presentations (September 2026 onward) — management updates on ambulatory/outpatient expansion following the August 2026 creation of the Ambulatory Operations Group under Charles Gressle, and on cost-control programs.
• Any federal legislative action to extend or restore ACA exchange subsidies, which would reverse the payer-mix headwind directly and likely trigger an EPS estimate revision cycle upward.
• Continued share repurchase execution — the EPS math is heavily buyback-driven (Q2 2026 net income +2.8% but EPS +11.6%), so sustained repurchase capacity is itself an earnings catalyst, contingent on the cash flow trend holding.
• Regulatory clarity on 2027-2028 Medicaid supplemental/state-directed payments — resolution either way removes a large overhang on the multiple.

• Payer mix deterioration runs worse than the current $1.0-1.2B estimate, forcing a second FY2026 guidance cut and pulling 2027 consensus EPS down with it; the stock has no valuation cushion to absorb this, trading at 14.25x versus a 13.63x 5-year average.
• Medicaid supplemental payment and state-directed payment reform in 2027-2028, which is a structural reimbursement risk the trailing financials cannot quantify and the deterministic score cannot see.
• Balance-sheet fragility masked by the buyback story: stockholders' equity of -$6.58B (2026-06-30), $38.87B of long-term debt, current ratio of 0.781, and only $1.01B of cash. Negative equity is a capital-allocation choice, not distress, but it does mean there is no book-value floor under the shares and no equity buffer if cash generation turns.
• Cash flow quality: Q2 2026 operating cash flow of $2,335M versus $4,210M in Q2 2025 (-44.5%), with trailing-four-quarter OCF down 6.8% YoY. If this reflects slower collections from a higher self-pay/uninsured mix rather than timing, buyback capacity and the FCF yield both shrink.
• Margin trajectory has already turned: operating margin compressed ~79bps YoY in Q2 2026 (15.16% vs 15.95%). If the 2024-2025 expansion phase does not resume, EPS growth becomes almost entirely a share-count story, which is a materially lower-quality earnings stream than the market is paying for.

HCA is a genuinely good operator — 18.5% ROIC, ~$6.0B trailing free cash flow (about a 6% yield at the 2026-09-13 price of $426.94), and a buyback program shrinking the share count fast enough to produce 11.6% EPS growth in a quarter where net income grew 2.8%. But good business is not the same as good entry point. The earnings stream is being reset by an ACA subsidy lapse whose full extent is still unproven, margins have already compressed year-over-year for two straight quarters, the balance sheet carries negative equity and $38.9B of debt, and the stock trades at 14.25x trailing earnings versus a 13.63x five-year average — you are paying a full price for a story that is one bad print away from being repriced. I would not buy here; I would wait for the late-October Q3 2026 report to confirm whether the uninsured headwind has stabilized, and would want either that confirmation or a pullback toward the low-$400s before treating this as a value opportunity rather than a value trap in progress.

Applied a 14.7x forward P/E — a modest premium to the 5-year average trailing P/E of 13.63x, justified by 18.5% ROIC, a ~6% trailing FCF yield, and ~3%/yr share-count reduction from buybacks, but capped by ACA and Medicaid reimbursement uncertainty — to FY2027E EPS of ~$30.50 (built from the $29.47 next-FY consensus plus buyback accretion as the ACA headwind partially annualizes), giving $448. Cross-checked two ways: 9.2x EV/EBITDA on ~$15.3B of forward EBITDA less ~$43B net debt yields ~$457/share, and $6.0B of trailing FCF at a 6.2% yield on 216.5M shares implies ~$448/share — so $448 is the center of a reasonably tight $445-460 cluster rather than a single-method artifact.